Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adhera Therapeutics, Inc.MRNA · Entity 127789 | Director | January 03, 2017 | January 04, 2017 |
| Cellectar Biosciences, Inc.CLRB · Entity 7572 | Consultant | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adhera Therapeutics, Inc.
Report date January 03, 2017 · Filed January 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.17 · Expires 2022-01-03 | Direct | 81,000 |
Reported balance
After 2017-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-03 · Grant · Acquired 81,000 · Balance 81,000 F1: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018.
Cellectar Biosciences, Inc.
Report date July 08, 2026 · Filed July 10, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2036-07-08 | Direct | 15,000 |
Reported balance
After 2026-07-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 15,000 · Balance 15,000 F1: This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENVEC INC
Report date June 16, 2017 · Filed June 20, 2017
Section 16 reporting ended · disclosed 2017-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,000 |
Reported balance
After 2017-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-06-16 · Exercise / conversion · Acquired 1,500 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | Direct | 1,207 |
Reported balance
After 2016-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-06-16 · Tax withholding · Disposed 793 · Balance 1,207 F1: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2017-06-16 · Disposition to issuer · Disposed 1,207 · Balance 0 F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 358 shares of Intrexon common stock having a market value of $8,170 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2017-06-16 | Direct | 0 |
Reported balance
After 2017-06-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-16 · Exercise / conversion · Disposed 1,500 · Balance 0 F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations.
F2: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 358 shares of Intrexon common stock having a market value of $8,170 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration").
F3: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration.
F5: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 9, 2026 01:00 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001104659-26-082009 · tm2620095-1_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Consultant 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires 2036-07-08 F1 · derivative.exercise_date: This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 21:00 UTC Amendment | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001104659-26-082761 · tm2620238-1_4aseq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Consultant 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common stock · 15,000 shares Expires 2036-07-08 F1 · derivative.exercise_date: This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:05 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001104659-25-014752 · tm256830-6_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-14 F1 · derivative.exercise_date: This option shall vest in full on February 14, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 21:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001104659-24-072883 · tm2417520-5_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-12-22 F1 · date: This option was contingently granted on December 22, 2023, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2024 Annual Meeting of Stockholders. Such stockholder approval was obtained on June 14, 2024. F2 · derivative.exercise_date: This option shall vest in full on December 22, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 28, 2023 Filed Jun 28, 2023 22:25 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001104659-23-075939 · tm2320030-3_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,885 Underlying: Common Stock · 25,000 shares Expires 2033-06-28 F1 · derivative.exercise_date: This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 24, 2022 Filed Aug 1, 2022 22:01 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 7,800 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001104659-22-084837 · tm2222253-3_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2032-06-24 F1 · derivative.exercise_price: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F2 · derivative.exercise_date: This stock option shall vest in full on June 24, 2023, subject to the reporting person's continued service through the applicable vesting date. F1 · derivative.underlying_shares: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. F1 · balance_after: Exercise price and quantity have been adjusted for the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:03 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 78,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001104659-21-088839 · tm2120855-4_4seq1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2031-06-30 F1 · derivative.exercise_date: This option shall vest on the first anniversary of the date of grant. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 20:24 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001104659-20-076875 · tm2023456d6_4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-24 F1 · derivative.exercise_date: This option grant shall vest over a period of three years from the grant date, with one-third vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:32 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 6,500 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001144204-19-031008 · tv523609_4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2029-06-13 F1 · derivative.exercise_date: Options vest on the one year anniversary of the date of grant. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:50 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001144204-18-053881 · tv504846_form4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-10-12 F1 · derivative.exercise_date: This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:32 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionStock Options (right to buy) · Derivative | 1,500 | $3.80 Strike: $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001159 · edgar.xml · derivative · entry 4 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2017-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, the vesting date of unvested stock options accelerated to vest and become exercisable as of the closing of the merger. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:32 UTC | GENVEC INC GNVC · Entity 175088 | Disposition to issuerCommon Stock | 1,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-17-001159 · edgar.xml · nonDerivative · entry 3 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: The shares of Common Stock were cancelled pursuant to the Agreement and Plan of Merger, dated January 24, 2017, among the Issuer, Intrexon Corporation ("Intrexon") and Intrexon GV Holding, Inc. (the "Merger Agreement") in exchange for (i) 358 shares of Intrexon common stock having a market value of $8,170 as of the close of trading on the date immediately prior to the effective date of the merger, and cash in lieu of fractional shares of Intrexon common stock, plus (ii) one contingent payment right (the "Merger Consideration"). F3 · shares: [footnote 2 continued] Each contingent payment right entitles the holder thereof to an amount equal to half of certain payments actually received by the registrant or its successor or any of their affiliates from or on behalf of Novartis Institutes for BioMedical Research, Inc. ("Novartis") under the Research Collaboration and License Agreement, dated January 13, 2010, as amended, between the registrant and Novartis, on account of milestone payments or royalties due in relation to the period ending June 16, 2019, divided by the number of shares of the regisrant's common stock having rights to the Merger Consideration, subject to any withholding of taxes required by applicable law. F4 · price: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:32 UTC | GENVEC INC GNVC · Entity 175088 | Exercise / conversionCommon Stock | 1,500 | $3.80 | $5,700.00 |
DisclosureSEC source: 0001123292-17-001159 · edgar.xml · nonDerivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2017 Filed Jun 1, 2017 22:02 UTC | Cellectar Biosciences, Inc. CLRB · Entity 7572 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001144204-17-030680 · v468269_4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-31 F1 · derivative.exercise_date: Options vest in equal annual increments over a period of three years from the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 18:21 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 81,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001493152-17-000142 · form4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: common stock · 81,000 shares Expires 2022-01-03 F1 · derivative.exercise_date: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017, and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 17:30 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001493152-16-015243 · form4.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 35,000 shares Expires 2021-11-15 Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 16:44 UTC | GENVEC INC GNVC · Entity 175088 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001140361-16-083399 · doc1.xml · derivative · entry 1 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-10-20 Read SEC document |
| June 16, 2016 Filed Jun 20, 2017 16:32 UTC | GENVEC INC GNVC · Entity 175088 | Tax withholdingCommon Stock | 793 | $7.19 | $5,701.67 |
DisclosureSEC source: 0001123292-17-001159 · edgar.xml · nonDerivative · entry 2 Loren Stefan · CIK 0001441500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207 F1 · kind: Withholding of Common Stock to pay exercise price and to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.